FORM 4

## **UNITED STATES SECURITIES AND EXCHANGE COMMISSION**

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

wasinington,	D.C.	20343	

ton, D.C. 20549	OMB APPROVAL
-----------------	--------------

- 1		
-1	î .	
	OMB Number:	3235-0287
	Estimated average bu	ırden
	hours per response:	0.5

## Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person* <u>MacKenzie Lloyd</u>			<u> </u>	2. Issuer Name and Ticker or Trading Symbol AQUINOX PHARMACEUTICALS, INC [							5. Relationship of Reporting Person(s) to Issuer (Check all applicable)  Director 10% Owner				
(Last) (First) (Middle)					AQXP ]  3. Date of Earliest Transaction (Month/Day/Year)						below)	(give title nief Operatin	Other (s below)	pecify	
C/O AQUINOX PHARMACEUTICALS, INC. 450 - 887 GREAT NORTHERN WAY					08/07/2018								ner Operatio	eg Officer	
(Street) VANCOUVER A1 V5T 4T5				4.	4. If Amendment, Date of Original Filed (Month/Day/Year)						Line	ndividual or Joint/Group Filing (Check Applicable e) X Form filed by One Reporting Person			
(City)		State)	(Zip)									Form fil Person	ed by More th	an One Report	ing
		Та	ble I - Non-D	Derivati	ve Se	ecurities	s Acc	quired, D	isposed (	of, or Be	neficially	Owned			
Date		Transaction ate Month/Day/		2A. Deemed Execution Date, if any (Month/Day/Year)		Code (Instr.		ities Acquir d Of (D) (Ins	ed (A) or str. 3, 4 and 5	Beneficia Owned Fo	Form (D) of ollowing (I) (In	m: Direct   I or Indirect   I Instr. 4)	7. Nature of ndirect Beneficial Dwnership		
							Code V	Amount	(A) o (D)	r Price	Reported Transacti (Instr. 3 a	on(s)		Instr. 4)	
			Table II - De						posed of converti			Owned			
1. Title of Derivative Security (Instr. 3)			Transa Code	saction Derivative I		Expiration Date (Month/Day/Year) U		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)		
				Code	v	(A)		Date Exercisable	Expiration Date	Title	Amount or Number of Shares		(Instr. 4)		
Stock Option (Right to Buy)	\$3.07	08/07/2018		A		145,000		(1)	08/06/2028	Common Stock	145,000	\$0.00	145,000	D	

## **Explanation of Responses:**

## Remarks:

/s/ Lloyd Mackenzie

08/09/2018

\*\* Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- \* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

<sup>1.</sup> The shares subject to this option shall vest and become exercisable at a rate of twenty-five percent of the total number of shares underlying the options on the one-year anniversary of August 7, 2018 (the "Vesting Commencement Date") and 1/48th of the total number of shares underlying the options each monthly anniversary of the Vesting Commencement Date thereafter for so long as the recipient of the option provides continuous service to the issuer, such that the total number of shares underlying the options shall be fully vested on the four-year anniversary of the Vesting Commencement Date.